Ausun Pharm(SH:603229)2019-04-24 16:00Financial Performance - Net profit attributable to shareholders was ¥7,781,920.30, representing a significant increase of 286.98% year-on-year[12]. - Operating revenue for the period was ¥58,365,261.76, reflecting a growth of 17.01% compared to the same period last year[12]. - Basic earnings per share increased to ¥0.05, up 400.00% from ¥0.01 in the previous year[12]. - The weighted average return on equity rose to 1.29%, an increase of 0.93 percentage points compared to the previous year[12]. - Net profit for Q1 2019 increased to ¥7,781,920.30, a 286.98% rise compared to ¥2,010,912.52 in Q1 2018, primarily due to increased revenue and reduced exchange losses[25]. - Total operating revenue for Q1 2019 was CNY 58,365,261.76, an increase from CNY 49,879,021.96 in Q1 2018, representing a growth of approximately 17.9%[45]. - The company's net profit attributable to shareholders for Q1 2019 was ¥7,781,920.30, a significant increase from ¥2,010,912.52 in Q1 2018, representing a growth of approximately 287.5%[47]. Cash Flow - Net cash flow from operating activities amounted to ¥24,290,993.20, a remarkable increase of 261.08% year-on-year[12]. - Operating cash flow for Q1 2019 was ¥24,290,993.20, up 261.08% from ¥6,727,385.16 in Q1 2018, mainly due to a decrease in payments for raw material purchases[25]. - Total cash inflow from investment activities was 46,074,138.36 RMB, while cash outflow was 50,122,455.37 RMB, resulting in a net cash flow of -4,048,317.01 RMB, an improvement from -16,949,397.36 RMB in the previous year[58]. - Cash inflow from financing activities amounted to 40,000,000.00 RMB, with cash outflow totaling 11,581,226.50 RMB, leading to a net cash flow of 28,418,773.50 RMB, compared to 56,366,762.04 RMB in Q1 2018[58]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥818,015,066.45, an increase of 2.00% compared to the end of the previous year[12]. - The company's total liabilities increased significantly, with a notable rise in accounts payable and accrued expenses[22]. - Total liabilities as of March 31, 2019, were ¥212,634,381.58, up from ¥204,379,898.41 at the end of 2018[35]. - Current liabilities totaled ¥196,518,054.69, including short-term borrowings of ¥72,000,000.00 and accounts payable of ¥109,614,396.89[65]. - Total liabilities amounted to 204,357,519.35, with current liabilities at 196,495,675.63[73]. Shareholder Information - The total number of shareholders at the end of the reporting period was 10,769[16]. - The largest shareholder, Zheng Zhiguo, holds 95,976,000 shares, accounting for 59.99% of the total shares[16]. Expenses - Tax expenses increased by 164.03% to ¥792,376.93, mainly due to an increase in tax liabilities during the period[22]. - Research and development expenses grew by 57.78% to ¥7,905,487.88, attributed to increased outsourced R&D costs[22]. - The company experienced a 50.73% increase in management expenses to ¥9,214,070.09, primarily due to higher employee compensation[22]. - Financial expenses decreased to ¥4,930,599.57 in Q1 2019 from ¥9,231,873.55 in Q1 2018, indicating a reduction of approximately 46.5%[45]. - The company reported a decrease in sales expenses to ¥1,252,573.79 in Q1 2019 from ¥925,845.02 in Q1 2018, which is a decrease of approximately 35.2%[51]. Other Income and Subsidies - The company received government subsidies amounting to ¥2,681,008.43, which are closely related to its normal business operations[12]. - Other income surged by 269.39% to ¥2,681,008.43, primarily due to an increase in government subsidies received[22]. - The company achieved other income of ¥2,681,008.43 in Q1 2019, compared to ¥725,793.14 in Q1 2018, representing an increase of about 269.5%[51]. Financial Instruments and Standards - The company's financial assets classified as "trading financial assets" decreased by 93.25% to ¥57,869.53 due to the implementation of new financial instrument standards[22]. - The company implemented new financial instrument standards starting January 1, 2019, affecting the classification of financial assets[73].